LANSING, Mich., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, announced today that the Company delivered the first shipment of its Monster Silk(TM) recombinant spider silk fiber to Warwick Mills, Inc. ("Warwick"). Warwick is a leader in the engineering and development of advanced technical textiles and protective materials.
The shipment represents a key step in the Companies' collaborative development initiative with Warwick, which will target the development of advanced spider silk based textiles.
"This first shipment of Monster Silk(TM) marks a new phase for Kraig and it demonstrates the efficacy of our research and development program and business model," said Kraig CEO and founder, Kim K. Thompson. "Warwick Mills is an innovator with a strong track record of developing and weaving advanced high strength textiles. So the delivery of this first small shipment of recombinant spider silk to them is a very exciting milestone in the commercialization of spider silk," concluded Thompson.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495 ir@KraigLabs.com
Source:Kraig Biocraft Laboratories, Inc